Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

  1. Lon S. Schneider3
  1. 1University of California, San Diego, California 92093
  2. 2Cleveland Clinic, Cleveland, Ohio 44195
  3. 3University of Southern California, Los Angeles, California 90007
  1. Correspondence: paisen{at}ucsd.edu

Abstract

In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.

Also in this Collection

    | Table of Contents

    This Article

    1. Published in Advance November 30, 2011, doi: 10.1101/cshperspect.a006395 Cold Spring Harb Perspect Med 2: Copyright © 2012 Cold Spring Harbor Laboratory Press; all rights reserved
    1. » Abstract
    2. Full Text
    3. Full Text (PDF)
    4. All Versions of this Article:
      1. cshperspect.a006395v1
      2. 2/3/a006395 most recent

    Article Category

    Updates/Comments

    1. Submit updates/comments
    2. No updates/comments published
    3. Alert me when Updates/Comments are published

    Subject Collections

    1. The Biology of Alzheimer Disease

    Share

    Richard Sever interviews Joan Brugge

    Current Issue

    1. May 2024, 14 (5)
    1. Current Issue